Use of angiotensin II receptor blockers in children- a review of evidence
Abstract
Abstract:
Background: The incidence of hypertension in the pediatric population has been increasing. Childhood blood pressure is
predictive of adult BP. The renin angiotensin aldosterone system pathway is important in the mediation of pediatric hypertension.
New therapies approved for adults are often used off label in children with little or no efficacy and safety data in the paediatric population The angiotensin receptor blockers has been shown to be effective and safe in the treatment of pediatric hypertension.
Objective: The objective of this review is to hig hlight available clinical evidence on the efficacy, safety tolerability and kinetics of
angiotensin receptor blockers in childhood hypertension and its antiproteinuric effect in renal disease.
Method: The search strategy wasbased on Pubmed, Medline database, Cochrane Library, manual, Google and Yahoo searches. We summarized ten randomized controlled trials (RCTs .The search was done in June 2014 and updated in January and May 2015 in English language .
Results: A total of 120 publications were accessed from which 68 references were included in the review. The design and outcome of ten key randomised trials are summarised. Randomised trials have demonstrated the efficacy of angiotensin receptor blockers in the pediatric population aged 1–16 years. This class of drugs reduce blood pressures in pediatric patients with hypertension and proteinuria in renal disease. Safety pharmacokinetic, dosage, and palatability of adult formulations for the paediatric age group are highlighted
Conclusion: Angiotensin receptor antagonists are useful effective and safe alternatives to available
antihypertensive therapy in paediatric population. Angiotensin receptor antagonists should however be prescribed cautiously for sexually active adolescent females due to concern about angiotensin receptor blocker fetopathy.
Keywords: Angiotensin receptor blockers, childhood hypertension, drug safety, drug efficacy, pharmacokinetics and renal diseases.
Downloads
Published
Issue
Section
License
This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 License, which allows others to remix, transform, and build upon the work even, commercially, as long as appropriate credit is given to the author, and the new creations are licensed under identical terms